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Abstract
Acute gout arthritis flares contribute dominantly to gout-specific impaired health-related quality of life, representing
a progressively increasing public health problem. Flares can be complex and expensive to treat, partly due to the
frequent comorbidities. Unmet needs in gout management are more pressing given the markedly increasing gout
flare hospital admission rates. In addition, chronic gouty arthritis can cause joint damage and functional impairment.
This review addresses new knowledge on the basis for the marked, inherent variability of responses to deposited urate
crystals, including the unpredictable and self-limited aspects of many gout flares. Specific topics reviewed include how
innate immunity and two-signal inflammasome activation intersect with diet, metabolism, nutritional biosensing, the
microbiome, and the phagocyte cytoskeleton and cell fate. The paper discusses the roles of endogenous constitutive
regulators of inflammation, including certain nutritional biosensors, and emerging genetic and epigenetic factors.
Recent advances in the basis of variability in responses to urate crystals in gout provide information about
inflammatory arthritis, and have identified potential new targets and strategies for anti-inflammatory prevention
and treatment of gouty arthritis.
Keywords: Gout flare, NLRP3 inflammasome, AMPK, PPAR-γ, PGC1B, Short-chain fatty acids, β-hydroxybutyrate,
miR-146a, miR-155, IL-37
Background
Acute gouty arthritis is a major and increasing public
health problem given the substantial rise in gout preva-
lence over the last two decades [1]. Acute gout flares are
the major contributor to gout-specific impaired health-
related quality of life [2]. In this context, flares can be com-
plex and expensive to treat [3], partly due to the commonly
associated comorbidities, including cardiovascular disease,
chronic kidney disease, and diabetes [4], and to frequent
contraindications to one or more of the standard oral
anti-inflammatory therapy options for gout (i.e., NSAIDs,
colchicine, corticosteroids) [5]. Moreover, responses to
these oral agents often take at least 12–24 hours to be
robust, and can take from several days to a week to be
complete [6]. Importantly, there has been a marked,
progressive increase in hospitalizations due to gout flares
over the last two decades, in stark contrast to the data
for decreased hospitalizations specifically for poorly
controlled flares of rheumatoid arthritis [7]. The capacity
of chronic gouty arthritis to cause joint damage and
functional impairment further adds to the societal and
financial impact of the disease.
The pathogenesis of gouty inflammation is relatively
well understood [8–10]. It is known that urate crystals
promote cleavage of C5 on their surface, catalyzing the
generation of C5a and C5b-9 involved in gouty inflamma-
tion [8]. There is also extensive knowledge of how the
crystals activate phagocytes, the role of inflammation
signaling and transcription factors, including mitogen
activated protein kinases and AP-1, the role of the master
transcriptional regulator NF-κB [8], and on the activation
of the NACHT-LRR-PYD-containing protein 3 (NLRP3)
inflammasome, with consequent IL-1β maturation and
secretion [10, 11]. Many other urate crystal-induced in-
flammatory mediators are well characterized, including
multiple prostaglandins, several leukotrienes (e.g., leuko-
triene B4) [8, 12], and a host of cytokines, including IL-8
and many other chemokines, IL-6, and TNF-α [8, 13].
Other noteworthy background observations include the
late dampening effects of TGF-β in experimental acute
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gout [8]. This review focuses on the most recent research,
which sheds new light on why human host responses to
tissue deposits of urate crystals in gout are so variable
in intensity, change in frequency between seasons, are
so often unpredictable in onset, and are characteristic-
ally self-limited. The rapidly emerging research in this
area points to multiple new targets and strategies for
the unmet needs in the optimal prevention and treat-
ment of gouty arthritis, as well as providing valuable
lessons about innate immunity in rheumatic disease in
general.
Urate crystal deposits often remain clinically silent
Advanced imaging approaches, using high resolution
ultrasound and highly specific dual energy CT (DECT),
have emerged as extremely sensitive and specific diagnos-
tic tools for urate crystal deposition in gout. A striking ob-
servation in several studies with each of these imaging
modalities is that many of those with asymptomatic hyper-
uricemia, and not simply with very high levels of serum
urate, have evidence for urate crystal deposition in articu-
lar as well as in certain periarticular tissue loci [14, 15].
For example, in a recent study [14], first metatarsophalan-
geal joint ultrasound was positive for urate crystal depos-
ition in 36% of patients with asymptomatic hyperuricemia
(defined as serum urate ≥ 6.9 mg/dL), but without sub-
stantial evidence of synovitis and bone erosion. In an-
other study of asymptomatic hyperuricemia [15], DECT
revealed urate crystal deposits in 24% of patients. DECTana-
lyses demonstrate that tendon urate crystal deposits, which
resolve relatively slowly with aggressive urate-lowering
therapy (ULT) [16], are a marker for symptomatic gout
[15]. However, ‘early gout’ (defined as ≤ 3 years disease
duration) and well-established ‘late gout’, both with mean
serum 7–7.5 mg/dL, have similar crystal volumes in
joints [15].
Novel findings, using DECT, have further indicated that,
in the absence of gout, urate crystals deposit in costal
cartilages and intervertebral disks in middle-aged men
[17], and at several sites of axial and peripheral joint in-
volvement in spondyloarthropathy and seronegative
rheumatoid arthritis patients [18, 19]. Nevertheless, the
mechanism and tissue effects of deposited urate crystals
in these conditions are unknown. Another provocative
study suggested the formation of urate crystals, studied
ex vivo, in circulating phagocytes of markedly hyperuri-
cemic human blood [20].
Volumetric analysis of articular urate crystal deposits
by DECT has suggested that there may be ‘threshold ef-
fects’ for expression of the gouty arthritis phenotype,
with greater urate crystal deposit volume detectable in
gouty joints compared to asymptomatic hyperuricemia
[15]. However, in patients with gout, both exogenous
and host factors are arrayed in opposition to promote
and limit inflammatory responses to significant volumes
of deposited urate crystals, including at specific sites in
the joint (summarized in Table 1, and discussed below).
The balance between these factors likely plays a core role
in determining the expression of the gouty arthritis
clinical phenotype.
Endogenous and exogenous promoters of gouty
inflammation
Acute gouty arthritis is a prototypical ‘early induced innate
immune response’, with periodic, recurrent, short-lived
‘auto-inflammation’, no clear protective immunity to urate
crystals, and cytokine-stimulated neutrophil-rich inflam-
mation [8–10]. Neutrophil ingress helps drive robust pain
responses [12]. Many different mediators are generated in
gouty inflammation, and they can have distinct effects
at differing phases of the process to initiate, amplify,
dampen, and extinguish acute gout [8–10]. Recent re-
search supports a new hypothetical model of major factors
constraining, igniting, and helping to terminate acute
gouty arthritis flares, and of multiple additional factors
that amplify or otherwise tune the inflammatory pheno-
type (Fig. 1). Essentially, innate immunity intersects with
nutrition, metabolism, and cell fate in phagocytes to shape
how the host responds to deposited urate crystals. Individ-
ual mediators, and their effects on the gouty inflammation
process, are cited in Table 1, and discussed below.
First signal NLRP3 inflammasome activators
Recent discoveries illuminate the complex alignments of
opposing endogenous and exogenous factors at several
steps in the gouty inflammation process (Table 1). The
canonical NLRP3 inflammasome response to the ‘second
signal’, provided by urate crystals, requires ‘first signal’
priming events, including increases in activation of NADPH
oxidase and NF-κB, expression of pro-caspase-1, pro-IL-1β,
and NLRP3 mRNA, and particle phagocytic capacity
[21–23]. Certain first signal NLRP3 inflammasome acti-
vators can promote and sustain chronic low-grade in-
flammation, clinically evident chronic synovitis in gout,
and acute inflammatory flares in response to deposited
urate crystals. These include C5a [24], GM-CSF [25],
and the TLR4 ligand and abundant neutrophil granular
protein heterodimer S100A8/A9 (also known as calpro-
tectin) [26]. These mediators are among the factors that
further amplify inflammation by promoting phagocyte
movement into the inflammatory locus in gout, and ac-
tivation of phagocytes at those sites (Fig. 1).
Exogenous, dietary-induced, first signal NLRP3 inflam-
masome activators include long-chain saturated fatty
acids such as the TLR2 and TLR4 ligand palmitate [23];
they also appear to include spikes in systemic levels of
the short-chain fatty acid acetate [27]. Such acetate
spikes can be pronounced (e.g., 20-fold rise) rapidly after
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alcohol intake. Increased acetate, which signals through
the G protein coupled receptor GPR43 [27], could con-
tribute to the association of acute gout flares with high
level consumption of all forms of alcohol [28].
Genetic factors
New findings highlight the genetic impact on the clinical
expression of the gouty arthritis phenotype (Table 1),
including arthritis flares frequently associated with
dietary excesses [29]. The nutritional biosensor peroxi-
some proliferator-activated receptor (PPAR)-γ is a ligand-
dependent nuclear receptor and transcription factor that
regulates insulin sensitivity, adipocyte differentiation, and
glucose homeostasis. PPAR-γ also exerts a variety of
anti-inflammatory effects, in part by transrepression of
numerous NF-κB target genes. These effects include
suppression of experimental gouty inflammation by some
PPAR-γ agonists, mediated in part by suppression of TNF-α
[30, 31]. Notably, urate crystals rapidly induce PPAR-γ in
monocytes in vitro [31]. However, the natural ligand(s) of
PPAR-γ that could limit gouty arthritis remain unclear.
In a study of a Chinese cohort [32], PPAR-γ co-activator
1B (PPARGC1B) gene variance permissive for inflam-
mation was increased in those with gout, with the
PPARGC1B risk A allele rs45520937 approximately
doubling the risk of gout. The PPARGC1B risk allele A
is common (13% in Han Chinese, 4% in Whites) [32].
Transfecting cDNA with this risk allele into cultured
human macrophage lineage cells augments inflamma-
tory responsiveness to urate crystals [32].
A small but significant increase in the risk of gout has
been linked with functional variants in the inflammasome
component caspase activation and recruitment domain
(CARD) gene CARD8, IL1B, and the TLR4 and TLR2
receptor complex co-receptor molecule CD14 [33].
Multiplicative interactions of the gout-associated IL1B
risk genotype with that of CARD8 amplify the risk of gout
[33]. In contrast, genetic variance in TLR4 has been linked
with gout risk in some populations, but with widely differ-
ing results, and the impact is less clear for the heritable
variance of TLR4 in gout [34].
Epigenetic factors
Epigenetic effects are increasingly well understood in
the regulation of inflammation, exemplified by the pro-
inflammatory effects of some class I histone deacetylases
involved in the ability of urate crystals to initiate phago-
cyte activation [35]. Significantly, phagocyte activation for
inflammation is mediated by miR-155. Indeed, peripheral
blood mononuclear cells (PBMCs) from gout patients and
mouse tissues from experimental acute gout have been
shown to have increased miR-155 compared to healthy
Fig. 1 Proposed new model of fundamental factors determining the variability in timing, extent, and duration of acute inflammatory responses
to tissue urate crystal deposits. The schematic depicts multiple, recently described mediators of the phenotype of acute gouty inflammation that
are discussed in detail in the text, with many cited in Table 1. In this model, acute gouty inflammation is depicted as a fire surrounding a woodpile that is
meant to pictorially represent tissue urate crystal deposits. The most recently discovered mediators of ignition of acute gouty inflammation, amplification
of the process, and damping and extinguishing of the response are listed in the schematic, cited in further detail in Table 1, and discussed at length in the
text. AMPK AMP-activated protein kinase, CARD8, Caspase recruitment domain-containing protein 8, Clec12a inhibitory C-type lectin receptor 12a, GM-CSF
granulocyte macrophage-colony stimulating factor, HDAC histone deacetylase, IFN-1 type I interferon, IL-1ra IL-1 receptor antagonist, MerTK Mer tyrosine
kinase receptor for phosphatidylserine, NET neutrophil extracellular trap, PPAR Peroxisome Proliferator-Activated Receptor γ co-activator 1β (PPARGC1B),
PMN neutrophil
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controls [36]. Urate crystals induce miR-155 in phagocytes
and, in turn, elevated miR-155 levels increase the capacity
of urate crystals to induce IL-1β and TNF-α; decreased
SH2-containing inositol 5’-phosphatase-1 has been shown
to be implicated in this mechanism [36].
Effects of urate levels and crystal morphology
It is well-recognized that ULT can precipitate more acute
gout flares. This may be mediated by inflammatory effects
through ULT-induced changes in tissue urate equilibrium
and remodeling of articular urate crystal deposits, leading
to greater accessibility of crystals to inflammatory cells.
Essentially, urate crystal deposits formed at different sites
within the joint (including synovial fluid, the articular car-
tilage surface, and within tendons and ligaments, often at
insertion sites) have different physical characteristics [37].
Urate crystals at sites of initial nucleation on templates
of collagen and proteoglycan-rich connective tissues and
urate crystals with a dense protein coating may have a dis-
tinct inflammatory potential from crystals at sites of sec-
ondary nucleation [37]. It is likely that dynamic changes in
urate crystal morphology develop not only with ULT, but
also with spikes in the level of hyperuricemia. Moreover,
hyperuricemia markedly increases the inflammatory po-
tential of exogenous urate crystals in experimental gout in
mice in vivo [38].
A high level of soluble urate, apart from promoting
urate crystal deposition, appears to exert a variety of prim-
ing effects on inflammation [38–40]. PBMCs of subjects
with asymptomatic hyperuricemia were observed to gen-
erate greater amounts of multiple inflammatory cytokines
than cells from healthy controls when stimulated ex vivo
[38, 39]. Moreover, elevated soluble urate suppresses
mononuclear phagocyte autophagy and IL-1ra expression
and, conversely, activates multiple inflammatory pathways
in mononuclear phagocytes, including NF-κB activity and,
via the AKT (protein kinase B) pathway and the proline-
rich AKT substrate 40 kDa (PRAS 40), activity of the
mammalian target of rapamycin [38, 39]. Soluble urate
may also activate the NLRP3 inflammasome under hyp-
oxic conditions [41]. However, the impact of hyperurice-
mia alone on inflammation requires further investigation.
In this context, physiologic concentrations of soluble urate
have been suggested to have anti-inflammatory as well as
chondroprotective effects [42].
Leukocyte senescence
Replicative senescence not only develops with aging, but
also with recurring and chronic inflammation. Senescence
promotes tissue inflammation, particularly by differenti-
ation to the senescence-associated secretory cellular pheno-
type [43]. A recent study suggests linkage of gouty arthritis
and cardiovascular disease in gout to leukocyte senescence
[44]. Specifically, PBMC senescence has been assessed by
quantification of telomere length and telomerase activ-
ity in a discovery cohort of Dutch patients with gout
(and healthy controls), along with a New Zealand repli-
cation cohort [44]. Gout patients have significantly shorter
telomeres, with telomere erosion being higher at all ages
in patients with the disease and being correlated with gout
flare frequency [44]. The shortest telomeres are seen in
gout patients with cardiovascular disease [44].
Endogenous and exogenous suppressors of gouty
inflammation
AMP-activated protein kinase (AMPK)
PPAR-γ is one of the various metabolic regulators that
influence gouty inflammation. Specifically, AMPK is a
nutritional biosensor that promotes healthy metabolic
adaptations to stress, including glucose transport, insu-
lin sensitization, lipid metabolism including β-oxidation
of fatty acids, mitochondrial function and biogenesis,
balanced cell growth, and autophagy [45]. AMPK is not
simply a metabolic ‘super-regulator’ but also suppresses
oxidative stress and inflammation [46, 47]. Active AMPK
also mediates some of the therapeutic effects of metformin
and the anti-inflammatory effects of methotrexate, sa-
licylates, and high-dose aspirin [46]. Activated AMPK
markedly suppresses mononuclear phagocyte responses
to urate crystals in vitro, including NLRP3 inflammasome ac-
tivation and IL-1β and chemokine release [47]. AMPK also
promotes anti-inflammatory M2 macrophage polarization
and autophagy [47]. Genetic AMPK α1 chain deficiency
markedly increases mouse inflammatory responses to urate
crystals in vivo [47]. Conversely, a pharmacologic AMPK
activator suppresses experimental gout-like inflammation
in vivo [47].
Caloric deprivation and exercise are among the factors
that elevate tissue AMPK activity levels by increasing
the cellular AMP:ATP ratio [45, 46]. Conversely, AMPK
activity at the tissue level is inhibited by dietary intake of
palmitate, fructose, and alcohol excess, as well as by ex-
posure of cells to IL-1β, TNF-α, and urate crystals in
vitro [45, 47]. The impact of nutritional biosensing by
AMPK on gout is likely substantial in a disease marked
by common metabolic co-morbidities and dietary excesses.
In this context, obesity, metabolic syndrome, type II dia-
betes, and hyperglycemia diminish tissue AMPK activity
[45]. Moreover, AMPK activity limits progression of several
common gout comorbidities, including non-alcoholic stea-
tosis and chronic kidney disease [48].
Emerging dietary factors
Dietary (e.g., in purine and overall caloric intake) and al-
cohol consumption restrictions, as well as a reduction in
obesity, are dietary measures that have an impact on
gouty inflammation [29, 30]. Recently, serum omega-3
fatty acid concentration was suggested to be inversely
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proportional to the risk of frequent acute gout flares [49].
Omega-3 fatty acids blunt NLRP3-mediated caspase-1 ac-
tivation and IL-1β release in response to urate crystals and
other agonists [50]. Internalization of omega-3 fatty acids
by the G protein-coupled receptors 120 (GPR120) and
GPR40, and signaling by their downstream scaffold
protein β-arrestin-2 (ARRB-2), are centrally implicated
in the mechanism [50]. ARBB-2 limits NF-κB activation,
and is directly associated with and inhibits NLRP3 [50]. In
addition, a ketogenic diet (involving substantial carbohy-
drate intake restriction), inhibits experimental gouty inflam-
mation via β-hydroxybutyrate and inhibition of NLRP3
inflammasome first-signal priming, as well as IL-1β release
from phagocytes [26].
Recent work has suggested beneficial effects of short-
chain fatty acids (including acetate and butyrate) in in-
flammation, including gouty arthritis [35, 51, 52]. Short-
chain fatty acids exert a variety of anti-inflammatory ef-
fects, mediated in part by limiting leukocyte activation
[35]. To date, butyrate is the best studied short-chain fatty
acid and is available not simply via intestinal microbiome
action on dietary fiber intake, but also from intake of milk
fat of grass-eating animals (e.g., cheese, butter, cream). Bu-
tyrate inhibits urate crystal-induced expression and release
of IL-1β from PBMCs in vitro, transduced by effects in-
cluding inhibition of certain class I histone deacetylases
[35]. Importantly, intestinal microbiome dysbiosis has
been reported in two studies of Chinese adults with gout
[53, 54]. Fecal material findings reported in gout subjects
have included depletion of Faecalibacterium prausnitzii,
which normally exerts anti-inflammatory effects via butyr-
ate production [53], and differences in several metabolites
that modulate inflammation (e.g., increased succinate,
which increases IL-1β via modulation of hypoxia inducible
factor-1α) [54].
In experimental gout-like inflammation in mice, a
high-fiber diet has been reported to induce more rapid
resolution, but not onset, of the urate crystal-induced in-
flammatory response [52]. These results were mimicked
by acetate administration, which was effective even after
injection of urate crystals into the knee joint, and at the
highest level of the inflammatory response [52]. The
contributing mechanisms include increased neutrophil
apoptosis and inflammation-dampening uptake of apop-
totic neutrophils by macrophages (‘efferocytosis’), with
associated decreases in NF-κB activity, and increased
production of certain anti-inflammatory mediators [52].
Thus, acetate has paradoxical effects on the inflamma-
tory response in experimental gout [26, 27] (Table 1).
IL-37 and alpha-1 antitrypsin
IL-37, a member of the IL-1 family, is an anti-
inflammatory cytokine differentially regulated during the
course of tissue inflammatory reactions, largely through
expression by epithelial cells and mononuclear leuko-
cytes [55, 56]. IL-37 suppresses multiple innate inflam-
matory responses in vitro and in vivo, acting partially via
inhibition of the NLRP3 inflammasome and activation of
suppressor of cytokine signaling 3 [55]. IL-37 actions are
mediated partly by the phosphatidylserine receptor Mer
receptor tyrosine kinase signaling, and enhanced expres-
sion of IL-1R8 [55]. Exogenous human IL-37 markedly
suppresses experimental urate crystal-induced inflamma-
tion in mice [55]. In a recent study of PBMCs from sub-
jects with acute gout, non-acute gout, non-acute gouty
arthritis, and healthy controls, IL-37 was reported as sig-
nificantly greater in the non-acute gouty arthritis patients
compared to acute gout and healthy controls [56], which
is in contrast to increases in IL-1β, IL-6, and TNFα in the
acute gout group.
Recently, a seasonal, summer drop in the circulating
protease inhibitor alpha-1 antitrypsin (and inversely higher
stimulated IL-1β production) has been linked with in-
creased summer flares of gout in a large European func-
tional genomics consortium study [57]. Alpha-1 antitrypsin
is anti-inflammatory, which acts partly by inducing IL-1ra
and inhibiting proteolytic generation of IL-1β, including in
response to urate crystals [58]. Moreover, the recombinant
human alpha-1 antitrypsin-IgG1 Fc fusion protein markedly
inhibits joint inflammation in experimental acute gouty
arthritis in mice [58].
Possible role of adaptive immunity (type I interferon and
CD41 T cells)
A fundamental endogenous mechanism limiting the
NLRP3-mediated inflammasome pathway in vitro and in
vivo is cognate adaptive immunity, which acts via ef-
fector and memory CD41 T cells and cell-to-cell contact,
and is mimicked by stimulation with selected TNF fam-
ily ligands (e.g., CD40L) [59]. Moreover, type I interferon
suppresses NLPR3 inflammasome activation and IL-1β
release [60]. As such, some adaptive immune responses
might help maintain clinical inflammatory quiescence of
subcutaneous tophi, in which granulomatous structures
have been described to have a coronal ring that includes
T cells surrounding a central core of massed crystals
[61]. The presence of B cells and plasma cells in the to-
phus corona zone suggests that some form of cognate
adaptive immunity could exist in tophi [61].
NETosis, neutrophil microvesicles, and apoptosis
Recent research has elucidated that neutrophils are re-
quired not only to fuel experimental gouty inflamma-
tion but also to limit it in vivo [24, 62, 63]. First, at
high neutrophil densities achievable in acute gouty
arthritis, urate crystals stimulate extracellular trap
formation (NETosis) and aggregation [62]. IL-1β is
among the stimuli that can induce NETosis. Generally
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pro-inflammatory, NETosis promotes endothelial damage
and thrombosis, in part via release of neutrophil elastase in
the extracellular web enriched in chromatin, and by anti-
microbial and inflammatory proteins [20, 64]. Complex ag-
gregated NET structures develop in gouty joint fluids and
tophi, and aggregated NET formation appears to promote
resolution of acute neutrophilic gout-like inflammation in
mice. Further, aggregated NET formation may also promote
clinically quiescent tophus deposition by trapping and de-
grading several inflammatory mediators [62]. Conversely,
failure of clearance of circulating urate microaggregates in
phagocytes has been suggested to promote NETosis, which
is toxic to the vasculature [20]. Second, the neutrophil
chemotaxin and activator C5a have been reported to in-
duce neutrophil-derived phosphatidylserine-positive
microvesicles early in the course of inflammation, in-
cluding peritonitis induced by urate crystals in mice
[24]. Such microvesicles suppress C5a priming of the
NLRP3 inflammasome and induction of IL-1β release
and neutrophil influx via Mer receptor tyrosine kinase
signaling [24]. These effects are shared by synthetic
phosphatidylserine-containing liposomes and by neutrophil-
derived microvesicles isolated from joint fluids of patients
with gouty arthritis [24]. Third, annexin A1 promotes
acceleration of neutrophil apoptosis and can combine
with acetate, transglutaminase 2, and the inhibitory C-type
lectin receptor 12a to promote associated efferocytosis and
resolution of the acute phase of experimental gouty inflam-
mation [63, 65, 66].
Epigenetic effects via miR-146a
Increased miR-146a suppresses multiple urate crystal-
induced inflammatory responses in vitro, including IL-
1β expression [67]. In a study of patients with gout,
miR-146a has been reported to be significantly increased
in PBMCs between flares compared to controls with
normal serum urate, hyperuricemia, and gout patients
during acute flares [67]. Moreover, miR-146a expression
is broadly detected in tophi [67]. Urate crystals induce
miR-146a in cultured mononuclear phagocytic cells [67].
However, tissue levels of this epigenetic transcriptional
suppressor of gouty inflammation decrease early in experi-
mental urate crystal-induced inflammation in mice [67].
Intersecting effects of therapeutics on gouty
inflammation
The mechanisms of action of the primary treatment op-
tions for prophylaxis and treatment of acute gout
clearly intersect with many of the novel inflammation-
mediating pathways cited above. Specifically, indometh-
acin, ibuprofen, and certain other NSAIDs activate
PPAR-γ [68].
Corticosteroids, which inhibit transcription of many
inflammatory genes, also regulate annexin A1 [69].
However, corticosteroids also paradoxically induce NLRP3
[70], which may contribute to rebound flares of acute
gout after steroid therapy is stopped [71]. Low doses of
colchicine suppress not simply neutrophil and endothe-
lial function, but also multiple inflammatory effects in
macrophages, transduced in large part by colchicine-
induced activation of AMPK [47].
With respect to investigational agents, randomized
clinical trials of the IL-1β-specific monoclonal antibody
canakinumab have demonstrated superiority compared
to a single dose of 40 mg triamcinolone acetonide in re-
ducing pain in acute gout and delaying time to next
acute gout flare [71]. Canakinumab is approved in Europe
as an option for acute gout therapy. Multiple retrospective
case series have reported on the efficacy of anakinra
(recombinant IL-1ra) in acute gout in many but not all
patients [72]. Failure in acute gout (but not for anti-
inflammatory flare prophylaxis) of the IL-1 blocker rilo-
nacept may have been due to binding of rilonacept to
IL-1ra [73]. Finally, the partial PPAR-γ agonist arhalofe-
nate, which is a uricosuric, has been reported to be as-
sociated with a decreased frequency of acute gout flares
in comparison to allopurinol in a Phase II randomized
controlled trial comparing ULT strategies and flare
prophylaxis [74].
Future directions of research
The emerging research reviewed here provides new con-
cepts and targets that could identify serum and circulat-
ing leukocyte biomarkers for the gout inflammatory
state. Circulating IL-8/CXCL8 has potential as a unique
cytokine biomarker for gout in the period between flares
[75]. In contrast, neither routine acute phase reactants
nor serum urate level have a clear role in assessing the
inflammatory state in gout, exemplified by increased
early flares in ULT and continuing chronic flares in many
despite a sustained urate at the desired levels. Several tar-
gets reviewed here could be ripe not only for development
as biomarkers of the baseline inflammatory state in gout,
but also for the clinical testing of new, selective, and safer
options for anti-inflammatory prophylaxis and therapy of
gout. Of great interest is the emerging generation of orally
bioavailable, small molecule NLRP3 inflammasome inhibi-
tors and inhibitors of NLRP3 inflammasome amplification
pathways [6, 76]. Direct, potent, and selective AMPK acti-
vators and IL-37 also have substantial potential. Other
mediators with likely impact, but not adequately investi-
gated to date as gout flare suppressors, include lipoxins
and maresins, as well as protectins and resolvins derived
from certain omega-3 fatty acids [77].
The potential impact on atherosclerosis in gout and hy-
peruricemia of circulating urate microaggregates in leuko-
cytes and associated NETosis [20] remains unclear. For
example, gout comorbidities and systemic inflammation
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with expression of pro-atherogenic cytokines IL-1β, IL-8/
CXCL8, and IL-6 have the capacity to accelerate athero-
genesis. An emerging line of investigation is linking in-
flammation and heritable urate transporter function in
gout [78]. Specifically, the functional Q141K variant of the
urate transporter ABCG2, which is strongly associated
with hyperuricemia and gout, and compellingly with early
onset and tophaceous gout, may inhibit autophagy and
modulate systemic inflammation [78]. Interestingly,
certain small molecules, including colchicine, invert de-
creases in ABCG2 141 K cell surface localization and
function [78]. Finally, it will be interesting to ascertain
whether the high frequency of nocturnal onset of acute
gout flares [79] is driven by decreases in endogenous
inflammation suppressors beyond altered activity of the
hypothalamic-pituitary-adrenal corticosteroid axis.
Conclusions
Multiple recent discoveries have revealed that urate crys-
tals form at a variety of unexpected sites, but without clear
inflammatory sequelae. Work in the last few years has elu-
cidated factors involved in the marked, inherent variability
of responses to urate crystals and onset, extent, and dur-
ation of flares of acute gouty inflammation. Knowledge of
how innate immunity intersects with diet, metabolism,
the microbiome, genetics and epigenetics, and phagocyte
fate in shaping inflammatory responses to urate crystal de-
posits in gout provides valuable lessons about inflamma-
tion, as well as potential new biomarkers and targets for
therapy in gout.
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